Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients
Incidence of Neurocognitive Deficits in Patients After Treatment for Retinoblastoma With Multiple Anesthesia Exposures
1 other identifier
observational
75
1 country
1
Brief Summary
The purpose of this study is to see if there is a difference between the development of the brain (neurodevelopment) in children who have been treated for retinoblastoma with multiple anesthetic exposures, compared with brain development in children who have never had anesthesia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 7, 2018
CompletedFirst Submitted
Initial submission to the registry
May 8, 2018
CompletedFirst Posted
Study publicly available on registry
June 6, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 7, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 7, 2026
CompletedJuly 3, 2025
July 1, 2025
8 years
May 8, 2018
July 2, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Comparing scores in neuropsychological testing results
The primary outcome is based on the Wechsler Intelligence Scale for Children, 5th edition (WISC-V) measured at follow up. The 5 primary index scores on the WISC-V (Verbal Comprehension, Visual Spatial, Fluid Reasoning, Working Memory, and Processing Speed) are based on 10 subtests and represent intellectual functioning in different cognitive areas. Similar to the FSIQ, the primary index scores are on a standard score metric with a mean of 100 (SD=15). The WISC-V consists of 16 subtests; each subtest is based on a scaled score metric with a mean of 10 and standard deviation (SD) of 3. Performance on these domain-specific subtests will be summarized and analyzed similarly to the FSIQ.
6 weeks
Interventions
the WISC-V assessment produces a Full Scale IQ (FSIQ) used for primary power consideration in this study. The FSIQ is the most comprehensive global ability score on the WISC-V, and it has been conventionally reported and interpreted as an estimation of overall intellectual ability
Used to assess verbal learning and memory in children and adolescents
Helps assess visual-motor skills in children and adults.
Measures dexterity
The Behavior Assessment System for Children/Parent Report is a questionnaire that assesses the social-emotional and behavioral functioning (e.g., anxiety, depression, attention, hyperactivity, adaptability, leadership, social skills, etc.) in children between the ages of 2 and 22 years, and is available in English and Spanish.
Eligibility Criteria
pediatric patients with retinoblastoma, between 6 and 16 years of age, at MSK.
You may qualify if:
- Age ≥ 6 and \< 17 years old
You may not qualify if:
- Diagnosis of any secondary disease associated with developmental delay
- History of second cancer diagnosis
- Legal Blindness
- Past surgery of any type, with the exception of enucleation for retinoblastoma
- Past exposure to anesthesia for surgical intervention
- More than one anesthesia encounter for surgical intervention before diagnosis at MSK
- Past External Beam Radiation for treatment of retinoblastoma
- Past systemic chemotherapy
- Non-native speaker of English; however, children whose parents speak only Spanish will be included, because the tests for parents are available in Spanish
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Vittoria Arslan Carlon, MD
Memorial Sloan Kettering Cancer Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 8, 2018
First Posted
June 6, 2018
Study Start
May 7, 2018
Primary Completion
May 7, 2026
Study Completion
May 7, 2026
Last Updated
July 3, 2025
Record last verified: 2025-07